Morphiex Biotherapeutics, a company developing the next generation of CD47 therapeutics for cancer, will participate in the 4th Annual Chardan Genetic Medicines Conference. Our CEO, Dr. Schwartz will be presenting a corporate overview of Morphiex and how its lead asset, MBT-001 is differentiated from competing...
Check out the new Biocentury article featuring Morphiex Biotherapeutics' as an emerging company which details how its CD47 immunotherapy platform is differentiated in both safety and efficacy for the treatment of cancer. Our lead drug candidate, MBT-001, is the only drug shown to block the...
Our CEO, Dr. Anthony Schwartz will be speaking at the 2020 CD47|SIRPa Summit to discuss the advantages of targeting SIRPa and thrombospondin-1 for the treatment of cancer. Morphiex's lead candidate (MBT-001) is the only drug that targets both SIRPa and thrombospondin-1. #CD47 #SIRPalpha #cancer #immunotherapyhttps://www.cd47sirpa.com/ ...
New Data with MBT-001 An oral presentation (#O8) featuring our #CD47 inhibitor (MBT-001) titled "The Thrombospondin-1/CD47 signaling axis serve as potential markers of immune checkpoint blockade response modulating immune cell bioenergetics in the tumor microenvironment" will be presented on Saturday, November 9th, 2019 at the Gaylord...
Check out our new publication in the Journal of Immunology & Immunotherapy demonstrating the synergy of Morphiex's CD47 inhibitor (MBT-001) with ipilimumab (CTLA4) and CAR-T. https://link.springer.com/article/10.1007/s00262-019-02397-7 MBT-001 was developed at the National Cancer Institute (NCI) at the National Institutes of Health (NIH). MBT-001 is exclusively...
Check out the new publication by our CEO, Dr. Anthony Schwartz which defines a new mechanism (Schlafen-11) through the CD47/thrombospondin-1 axis that is important for therapeutic resistance in cancer. Morphiex's MBT-001 is the only drug that blocks "Don't eat me" and thrombospondin-1 (TSP-1). This study...
Our lead drug, MBT-001 was recently featured in Frontiers in Immunology for enhancing NK cells through the CD47-TSP-1 pathway. MBT-001 is the only CD47 treatment modality that inhibits both SIRPa "Don't eat me" and TSP-1, thereby eliciting the full cancer-killing potential of CD47. https://www.frontiersin.org/articles/10.3389/fimmu.2018.02985/full ...
Morphiex is excited to announce our lead drug, MBT-001 was recently published in Breast Cancer Research and Treatment. In summary, MBT-001 inhibited tumor growth and metastasis alone and in combination with chemotherapy. https://www.ncbi.nlm.nih.gov/pubmed/30056566 ...
240 Newbury Street, 2nd Floor
Boston, MA
info@morphiex.com
